🇺🇸

US SEC Filing Intelligence

· daily

US SEC Trading Suspension Halt Orders — April 30, 2026

Across four 8-K filings in the USA Trading Suspensions stream, small-cap Nasdaq-listed companies face mounting compliance pressures, with 3/4 (Elite Express, Stardust Power, American Resources) receiving deficiency notices for bid price, market value/listed securities (MVLS), equity/net income, and late 10-K filing, but all granted cure periods extending to October 2026 with no immediate trading halts or delistings. Innventure stands out positively with board refresh appointing operations and finance experts amid shareholder engagement, contrasting sector governance strains. No period-over-period financial trends (YoY/QoQ revenue, margins) or insider trading activity reported across filings, limiting quantitative growth insights, though forward-looking compliance deadlines create a catalyst calendar clustered in Q3/Q4 2026. Capital allocation details absent, but operational highlights like Stardust's Lithium Refinery Project support signal potential turnaround paths. Portfolio-level pattern: emerging growth companies vulnerable to Nasdaq rules 5550/5250, implying heightened delisting risk and volatility; investors should prioritize monitoring for cure success amid mixed/negative sentiment (avg materiality 8.25/10). Market implications include short-term trading stability but elevated long-term suspension risks, favoring defensive positioning.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 30, 2026

Across 48 filings in the USA Corporate Distress & Bankruptcy stream (41 new), the dominant theme is corporate resilience through aggressive debt refinancing, facility expansions, and capital raises, with 12+ companies amending/extending credit lines (e.g., FTAI Aviation's $2.025B oversubscribed facility up from $400M) amid few outright bankruptcies but notable Nasdaq compliance failures. Period-over-period trends show mixed revenue (e.g., Martin Marietta +17% YoY to $1.36B, ProPetro -7% QoQ to $271M) and profitability (e.g., Tiptree EPS +162% YoY to $0.34, BayFirst net loss widened to $5.7M QoQ), with EBITDA pressures in energy (ProPetro -29% QoQ) offset by strong cash flows (Martin Marietta ops cash record $227M). Capital allocation leans toward deleveraging (FTAI Infra selling for $1.52B to repay $300M debt) and shareholder returns ($251M Martin Marietta Q1). Forward-looking catalysts cluster in Q3 2026 (M&A closings like ACRES/ACC, MARA/Long Ridge), signaling potential turnarounds, though Nasdaq delistings/threats (5 cases) and covenant waivers (Trinseo) flag ongoing distress risks. Portfolio-level, real estate/finance sectors show 8/10 amendments positive for liquidity, while small caps face equity dilution from raises. Implications: Buy dips in refinancing winners, short Nasdaq laggards; alpha in accretive M&A.

48 high priority 48 total filings
· daily

US Executive Officer Management Changes SEC — April 30, 2026

Across 43 filings in the USA Executive & Director Changes stream (40 new since last brief), the dominant theme is a surge in C-suite transitions, with 18 CFO/CEO/President appointments or changes (e.g., Entegris, Eos Energy, ResMed, Teleflex, Nexgel, Amtech, Red Robin, Halozyme) and 12 retirements/resignations/transitions (e.g., Matrix Service, NeuroOne, Marcus Corp, Recursion founder), signaling proactive leadership refreshes amid stable-to-growing operations. Period-over-period trends where reported show revenue growth averaging +8.7% YoY (Kirby +7.5%, CCC +12%, Select Medical +5%, ResMed gross margins 62-63% reiterated), but mixed margins (Kirby distribution -60 bps to 6.7%, Select op income -12.7% YoY). Annual meetings (12 filings) overwhelmingly passed director elections (>90% approval avg), equity plan expansions (e.g., Chemours +6.4M shares, RLJ +4.8M), and say-on-pay, with positive sentiment in 65% of filings. Capital allocation leans shareholder-friendly: dividends maintained/declared (BorgWarner $0.17, Select $0.0625, Kirby $52.7M buyback), buybacks (Teleflex $1B), no cuts noted. No widespread insider selling; equity grants/RSUs common (Vuzix CEO 477k RSUs). Implications: Bullish for sectors like healthcare/tech with experienced hires boosting execution, watch small caps for transition risks, portfolio-level alpha from pre-close catalysts like Q1 10-Qs and May-June starts.

43 high priority 43 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 30, 2026

Across 43 SEC filings on USA Board Room Changes from April 2026, a dominant theme is high CFO turnover with 15+ appointments or transitions (e.g., Entegris, Eos Energy, ResMed, NEXGEL), often featuring executives with 20-30+ years experience from blue-chip firms like Medtronic, J&J, signaling strategic upgrades amid growth pivots. Annual shareholder meetings (12+ filings) showed robust support for director elections (avg 95%+ FOR), equity plans, and say-on-pay, underscoring board stability. Period-over-period trends mixed: revenue growth in 4/6 reporting firms (CCC +12% YoY, Kirby +7.5% YoY, Select Medical +5% YoY), but margins compressed (Kirby distribution -60 bps YoY, Select ops income -12.7% YoY). Positive sentiment prevails (25/43 filings), with capital allocation supportive (Kirby $52.7M buybacks, BorgWarner $0.17 div, Select $0.0625 div). Implications: Bullish for healthcare/tech leadership refreshes, watch energy/industrials for transition risks; portfolio trend toward stronger governance boosting M&A appeal.

43 high priority 43 total filings
· daily

US Merger & Acquisition SEC Filings — April 30, 2026

Across 9 US M&A filings on April 30, 2026, a surge in transaction completions dominates, with 4 divestitures generating ~$2.4B in cash proceeds (SM Energy $950M, Spire $215M, Perrigo €306M net, Golden $2.75/share dividend), funding debt reduction, redemptions, and acquisitions amid portfolio streamlining. Positive sentiment prevails in 5/9 cases (SM Energy, Spire, Perrigo, Plutonian SPAC IPO, Bakkt acquisition), contrasting mixed/neutral in mergers involving dilutions or spin-outs (Golden, SOBR Safe 98% dilution, Coeptis pro forma op loss worsening YoY). Period comparisons highlight Coeptis Therapeutics' pro forma 2025 net loss improvement to $(9.1M) from $(12.3M) but operating loss deterioration to $(10.0M) from $(5.1M) YoY, signaling persistent unprofitability post-spin-out. SPAC activity intensifies with Plutonian's $100M IPO and SIM's deadline extension to 2027, while energy firms (SM, Spire) advance $1B+ divestiture targets. Capital allocation trends favor debt deleveraging (SM $819M notes redemption, Perrigo debt reduction) over dividends/buybacks, implying fortified balance sheets but limited shareholder returns. Market implications include alpha from post-M&A catalysts like redemptions and approvals, with watch for Q3 2026 closings amid high materiality (avg 8.7/10).

9 high priority 9 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 30, 2026

Across 50 overnight SEC filings for Q1 2026, overarching themes include robust revenue growth averaging ~10-15% YoY in tech giants (Amazon +16.6%, Alphabet +21.8%, KLA +11.5%) and select healthcare (Glaukos +41.2%, ImmunityBio +700%), contrasted by widespread margin compression and operating losses in industrials (Pilgrims Pride op inc -59.8%, Titan op loss on impairments), consumer (Chipotle NI -21.7%), and healthcare (Anika op loss +28%). Capital allocation leans shareholder-friendly with buybacks (Amazon none but prior, News Corp $1B program, KLA $1.72B), dividends (Ford cut to $0.15, NorthWestern +2%), and repurchases across banks (First Northern 6%, Southside none in Q1). Mixed sentiments dominate (28/50 mixed), but positive outliers signal resilience in cloud/AI (Alphabet Cloud +63.4%) and insurtech turnarounds (Hippo NI positive vs prior loss). SPAC post-IPO losses (QDRO, RF Acquisition) and shelf registrations (Veradermics +$57M, Vivos pivot) highlight fundraising amid going concern risks. Portfolio-level trends show QoQ cash declines in 12/20 Qs, but op cash improvements in 8/15, implying capex/reinvestment pressures; watch earnings calls today (Pilgrims, CIMPRESS) for guidance clarity.

27 high priority 23 medium 50 total filings
· daily

Biotech Small-Cap Approvals — April 29, 2026

The April 29, 2026 period recorded 1 FDA approval in the Biotech Small-Cap stream: 0 NMEs, 0 biosimilars, 0 label expansions, and 1 other. Alembic's FINGOLIMOD HYDROCHLORIDE received fallback approval, noted as a biosimilar in summary but categorized as other, delivering a neutral signal (strength 5/10, materiality 5/10) with all commercial metrics NOT_DISCLOSED. No dominant therapeutic area theme emerges from this lone approval, likely in neurology/MS given the drug's profile. The highest-conviction signal is Alembic's neutral market entry for FINGOLIMOD HYDROCHLORIDE, posing limited upside for the entrant while flagging mild competitive pressure on originator Novartis' Gilenya. Key risk/watch item is originator revenue erosion risk upon Alembic launch, balanced against unknown entrant pricing power.

1 total filings
· daily

New Drug Approvals (Original) — April 29, 2026

The FDA issued 1 approval from April 29 to April 29, 2026, categorized as 0 NMEs, 0 biosimilars, 0 label expansions, and 1 Other. ALEMBIC's FINGOLIMOD HYDROCHLORIDE represents a fallback approval, delivering a neutral investment signal (strength 5/10, materiality 5/10) with no disclosed peak sales, exclusivity, pricing, or market position data. No dominant therapeutic area theme emerges from this lone approval. The highest-conviction signal is ALEMBIC's FINGOLIMOD HYDROCHLORIDE approval, implying modest entry potential in an established market without near-term catalysts. Key risk/watch item: Lack of commercial transparency (all metrics NOT_DISCLOSED) warrants monitoring for launch execution risks.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — April 29, 2026

HHS awarded a single $92,501,232 cost-sharing contract to Basilea Pharmaceutica International Ltd (parent: Basilea Pharmaceutica AG) via BARDA, representing 100% civilian healthcare R&D funding with zero defense exposure. This full and open competition award for antimicrobials R&D against resistant fungal and bacterial infections provides long-term revenue visibility through 2031 (or potentially 2035), with only $36.2M outlayed to date and annual estimates of $13.2M (base) to $24.3M (full options). The highest-conviction bullish signal is the $267.6M ceiling potential, signaling BARDA's commitment to health preparedness. Key watch item: progress on option exercises and performance milestones amid R&D execution risks.

1 total filings
· daily

New Federal Contractors — April 29, 2026

These three new federal contracts totaling $259,112,045 in obligations are entirely civilian (0/3 defense-related), spanning NASA, HHS/BARDA, and Department of State with an average signal strength of 5.7/10. The dominant theme is long-duration R&D and IT services in health preparedness and national security support, led by Basilea Pharmaceutica International Ltd's $92.5M BARDA award for antimicrobials R&D—the highest-conviction bullish signal due to its $267.6M ceiling and 7-11 year horizon. Neutral signals dominate from historical LJT & Associates ($94.6M NASA, ended 2019 with low $8.8M outlay) and ongoing Idemia National Security Solutions ($72M State Dept, $18.2M outlayed through 2026). Key risk: stalled outlays on LJT and Idemia signal execution hurdles; watch Basilea option exercises toward $267.6M.

3 total filings
· daily

Significant Contract Modifications ($10M+) — April 29, 2026

These three significant contract modifications total $259,112,045 in obligations, entirely civilian with zero defense-related awards across NASA, HHS/BARDA, and Department of State. Dominant themes include health preparedness R&D, historical space launch operations, and ongoing facial recognition IT integration. The highest-conviction signal is bullish for Basilea Pharmaceutica International Ltd's $92.5M BARDA award for antimicrobials R&D, offering multi-year revenue potential up to $267.6M ceiling through 2035. Neutral signals dominate for LJT & Associates ($94.6M NASA, low outlays) and IDEMIA National Security Solutions ($72M State Dept, partial funding). Key watch item: option exercises and outlay progress across all, given low disbursements relative to obligations (e.g., only $8.8M outlaid on LJT's $94.6M).

3 total filings
· daily

Contract Deobligations Alert — April 29, 2026

This Contract Deobligations Alert covers $259,112,045 in total obligations across three civilian contracts from NASA, HHS/BARDA, and the Department of State, with zero defense-related awards. The dominant theme is long-duration civilian R&D and IT services, highlighted by Basilea Pharmaceutica International Ltd's $92.5M bullish BARDA award for antimicrobials R&D against resistant infections, offering the highest-conviction growth signal with potential upside to $267.6M ceiling through 2035. Neutral signals dominate from historical LJT & Associates' $94.6M NASA launch support contract (ended 2019 with minimal $8.8M outlay) and ongoing Idemia National Security Solutions LLC's $72M State Department facial recognition integration (partial $18.2M outlay to 2026). A key risk is low outlay pacing across all contracts, signaling potential deobligation or execution hurdles. Investors should watch BARDA option exercises for Basilea as the primary near-term catalyst amid civilian agency priorities.

3 total filings
· daily

Contract Option Exercises — April 29, 2026

These three contract option exercises total $259,112,045 in obligations, entirely civilian with zero defense-related awards across NASA, HHS/BARDA, and Department of State. The dominant theme is long-duration civilian R&D and support services in health preparedness, space operations, and IT security, highlighted by a highest-conviction bullish signal on Basilea Pharmaceutica International Ltd's $92.5M HHS/BARDA award for antimicrobials R&D amid resistant infections. Neutral signals dominate for LJT & Associates ($94.6M NASA, historical with low outlays) and IDEMIA National Security Solutions ($72M State Dept, partial funding). Key watch item: progress on option exercises and outlays, especially Basilea's path to $267.6M ceiling through 2035.

3 total filings
· daily

Federal IT & Cybersecurity Contracts — April 29, 2026

The analyzed contracts total $72,032,459 in obligations, representing a fully civilian award with 0/1 defense-related, centered on the Department of State's ACQUISITIONS - AQM MOMENTUM office. IDEMIA NATIONAL SECURITY SOLUTIONS LLC secured a firm fixed price delivery order for facial recognition system integration with visa and passport processes, offering multi-year revenue visibility through 2026-09-29 but with only $18,176,969 outlayed to date. The highest-conviction signal is neutral (6/10 strength), highlighting steady operational support revenue in Federal IT & Cybersecurity without defense exposure. A key risk is high pricing risk on the firm fixed price structure, potentially pressuring margins if costs overrun.

1 total filings
· daily

All HHS Contracts — April 29, 2026

HHS obligated $92,501,232 across 1 contract during the period, representing 100% civilian spending with 0 defense-related awards. The dominant theme is BARDA-funded R&D for antimicrobials targeting resistant fungal and bacterial infections, led by a single high-materiality award to Basilea Pharmaceutica International Ltd (parent: Basilea Pharmaceutica AG). This delivers the highest-conviction bullish signal via long-term cost-sharing funding under full and open competition, with only $36,222,783 outlayed to date against a potential $267,582,260 ceiling including options. Annual revenue potential is estimated at ~$13.2M/year through 2031 or ~$24.3M/year if fully realized to 2035. Key watch item: progress on option exercises and performance milestones amid R&D execution risks.

1 total filings
· daily

High-Value Federal Grants ($5M+) — April 29, 2026

Three high-value civilian federal contracts totaling $259,112,045 obligation (0/3 defense-related) highlight diverse non-defense spending: NASA's $94.6M historical award to LJT & Associates for space launch support (neutral signal), HHS/BARDA's $92.5M bullish R&D grant to Basilea Pharmaceutica International Ltd for antimicrobials, and State Department's $72.0M ongoing IT delivery order to IDEMIA National Security Solutions LLC for facial recognition integration. Dominant sector theme is civilian R&D and tech services, with BARDA health preparedness as the standout. Highest-conviction signal is bullish long-term funding for Basilea ($92.5M obligated, potential $267.6M ceiling to 2035). Key risk is low outlay progress across contracts (e.g., only $8.8M of LJT's $94.6M and $36.2M of Basilea's $92.5M disbursed), warranting watches on option exercises and performance milestones.

3 total filings
· daily

General Federal Contracts — April 29, 2026

This digest covers $259,112,045 in three civilian federal contracts (0/3 defense-related) awarded to distinct recipients across NASA, HHS/BARDA, and Department of State, highlighting long-duration R&D and IT support themes with average signal strength of 5.7/10. The highest-conviction bullish signal stems from Basilea Pharmaceutica International Ltd's $92.5M HHS/BARDA cost-sharing contract for antimicrobials R&D, offering potential upside to $267.6M through 2035 amid health preparedness priorities. Neutral signals dominate from LJT & Associates' historical $94.6M NASA launch support contract (ended 2019 with low $8.8M outlay) and IDEMIA National Security Solutions' $72M State Department facial recognition delivery order (ongoing to 2026 with $18.2M outlay). A key risk is limited outlay progress on older contracts, warranting watches on option exercises and follow-ons for revenue realization.

3 total filings
· daily

All NASA Contracts — April 29, 2026

NASA obligated $94,578,354 across 1 contract during the period April 29, 2026 to April 29, 2026, representing a 100% civilian split with 0 defense-related awards. The sole award went to LJT & Associates, Inc. from NASA Goddard Space Flight Center for the $94,578,354 IGF::Range Operations Contract Bridge (ROC-B) supporting launches at Wallops Island, VA. This historical cost-plus-fixed-fee contract (awarded 2016, ended 2019) carries a neutral investment signal (strength 4/10) due to its private recipient status and limited ongoing implications. Highest-conviction signal is neutral past revenue potential (~$31.5M/year est.) for LJT amid low outlays of only $8,769,312 against the obligation. Key risk is execution shortfalls evidenced by minimal outlays and expired performance period, warranting watch on follow-on opportunities.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 29, 2026

Across 43 filings from S&P 500 Technology stream (with broader exposure via 13Fs and proxies), dominant themes include robust cloud/AI growth in Microsoft (revenue +18% YoY, Azure +40%, AI run-rate +123% to $37B) contrasting mixed semiconductor results like Qualcomm's -3% YoY revenue amid handset weakness but +38% Automotive. Period-over-period trends show 4/6 key tech firms with double-digit YoY revenue growth (avg +14%), margin stability or expansion in leaders like KLA (+11.8% non-GAAP EPS), aggressive capital returns ($10.2B Microsoft, $20B new Qualcomm buyback, $7B KLA), and raised guidance (SBA FY AFFO/share, KLA Q4 revenue). Institutional 13Fs highlight sustained tech conviction (R Squared $4.78B Apple/$2.62B MSFT, Vanguard 7.48% Apple). Non-tech filings reveal dividend hikes (CPKC +17.5%, KLA to $2.30, ACNB $0.42+$0.50 special) but declines elsewhere (Cumulus -12.2% revenue, Oxford NAV -22% QoQ). Portfolio implications: overweight AI/cloud leaders amid sector rotation; monitor semiconductor recovery and bankruptcy risks in adjacent media.

12 high priority 31 medium 43 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 29, 2026

Across 38 filings from NASDAQ-100 and related constituents, Big Tech dominates with robust revenue growth (e.g., Meta +33% YoY, Alphabet +22% YoY, Microsoft +18% YoY, Amazon +17% YoY) fueled by AI, cloud, and ads, though offset by surging capex (Meta $125-145B FY26, up from prior) and flat margins; cyclical sectors show mixed results with declines in handsets (Qualcomm -13% YoY) and media (Cumulus -12.2% YoY amid bankruptcy). Period-over-period trends reveal 12/20 earnings reporters posting YoY revenue growth averaging +15%, but margins compressed in 8 cases (avg -50 bps) due to opex/investments; guidance raised in 6 firms (ADP to 6-7% rev, SBA AFFO $11.93-12.38). Capital allocation remains shareholder-friendly with dividend hikes (CPKC +17.5%, Alphabet +5%), massive buybacks (Qualcomm new $20B auth, MSFT $10.2B returned), and compliance wins (MultiSensor AI Nasdaq regain). Portfolio-level patterns highlight AI-driven outperformance in cloud (Azure +40%, AWS +28%, Google Cloud +63%) vs weakness in traditional media/auto handsets; implications favor long tech/AI exposure but monitor capex drag and bankruptcy spillovers.

12 high priority 26 medium 38 total filings